🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial

  2. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  3. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Solriamfetol 150 MG

    Axsome Therapeutics

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial

  5. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  6. Somatostatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gallbladder Neoplasms

    phase 3 small molecule completed

    1 trial

  7. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Neoplasms

    phase 3 other completed

    1 trial

  8. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mediastinal Neoplasms

    phase 3 other active

    1 trial

  9. Surgery and HIPEC with Lobaplatin

    Universal Integrated

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  10. TECFIDERA

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  11. TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  12. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  13. TROPICAMIDE, Vehicle for cenegermin drug product, COLIROFTA ANESTÉSICO DOBLE 1 MG/ML + 4 MG/ML COLIRIO EN SOLUCIÓN, OXERVATE 20 micrograms/ml eye drops, solution

    Dompe' Farmaceutici S.p.A.

    Persistent Corneal Epithelial Defect (PCED)

    phase 3 small molecule active

    1 trial

  14. Tamoxifen

    Pfizer

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  15. Terazosin

    Hospital Authority, Hong Kong

    Stent Related Symptoms

    phase 3 small molecule active

    1 trial

  16. Teriflunomide

    Merck KGaA, Darmstadt, Germany

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  17. Tiaoshen Anti-cancer Granules

    The First People's Hospital of Lianyungang

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  18. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  19. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  20. Trastuzumab Deruxtecan

    AstraZeneca

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  21. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  22. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  23. Two Anti-angiogenesis Drugs（Endostar and Thalidomide）

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 small molecule active

    1 trial

  24. UI05MSP015CT

    United Therapeutics Europe Ltd

    Functional Dyspepsia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources